CMPX
Compass Therapeutics, Inc.5.24
+0.16+3.15%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
932.00MP/E (TTM)
-Basic EPS (TTM)
-0.45Dividend Yield
0%Recent Filings
8-K
Q3 loss widens on R&D surge
Compass Therapeutics reported a Q3 2025 net loss of $14.3 million, up from $10.5 million last year, driven by $12.8 million in R&D expenses amid pipeline advances. Tovecimig's COMPANION-002 trial shows lower mortality, with OS and PFS data due late Q1 2026, potentially supporting a BLA filing in H2 2026 for advanced biliary tract cancer. CTX-8371's Phase 1 revealed a new response in a third indication, no DLTs, and expansions in NSCLC and TNBC starting Q4 2025. Cash stands at $220 million, funding operations through 2028.
10-Q
Q3 FY2025 results
Compass Therapeutics posted a Q3 net loss of $14.3 million, up 36% year-over-year from $10.5 million, driven by research and development expenses climbing 49% to $12.8 million amid ramped-up spending on CTX-10726 and tovecimig programs. Operating loss widened to $15.8 million from $12.2 million, while interest income dipped 11% to $1.6 million on shifting cash balances. Year-to-date, net loss reached $50.8 million, 48% higher than 2024's $34.3 million, with no licensing revenue after last year's $0.9 million milestone. Cash burn held steady at $35.9 million for the nine months, offset by $129 million from an August equity offering that boosted liquidity to $220 million, funding operations into 2028. No debt weighs on the balance sheet. Pipeline advances steadily. Clinical setbacks could stall momentum.
8-K
Upsized $120M offering priced
Compass Therapeutics priced an upsized public offering on August 12, 2025, selling 33.29 million common shares at $3.00 each and pre-funded warrants for 6.71 million shares at $2.9999, expecting $120 million in gross proceeds before expenses. Net proceeds of $112.5 million will fund commercial preparations, clinical development, and operations, extending cash runway into 2028. The deal closes August 14, subject to conditions. Yet risks could burn cash faster.
10-Q
Q2 FY2025 results
Compass Therapeutics posted a Q2 net loss of $19.9M, up from $13.1M last year, as R&D expenses climbed 47% to $16.4M on manufacturing for tovecimig and new CTX-10726, while licensing revenue dried up after a $0.9M milestone in 2024. YTD net loss widened to $36.5M from $23.9M, with operating cash burn steady at $25.0M versus $24.6M prior year. Cash and equivalents dipped to $22.9M, but total liquidity held at $101M with no debt, funding operations into 2027. Pipeline momentum builds: tovecimig's biliary cancer trial hints at OS benefits, CTX-8371 shows deep responses in NSCLC and TNBC. No non-GAAP metrics disclosed in the 10-Q. Yet regulatory pricing pressures loom large.
8-K
Q2 loss widens on R&D
Compass Therapeutics reported Q2 2025 net loss of $19.9 million, up from $13.1 million last year, driven by $5.2 million higher R&D on manufacturing for tovecimig and CTX-10726. Tovecimig's Phase 2/3 trial in biliary tract cancer showed fewer deaths than projected, delaying OS and PFS analyses to Q1 2026 while hinting at survival benefits. CTX-8371 notched deep partial responses in NSCLC and TNBC patients post-checkpoint therapy. Cash stands at $101 million, funding into 2027. Pipeline advances steadily.
IPO
Employees
Sector
Industry
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CGEN
Compugen Ltd.
1.49-0.01
CMPS
COMPASS Pathways Plc - American
6.39-0.20
CNTX
Context Therapeutics Inc.
1.10-0.03
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
IMTX
Immatics N.V.
10.09+0.11
MRKR
Marker Therapeutics, Inc.
1.27-0.12
SMMT
Summit Therapeutics Inc.
17.23-0.15
TECX
Tectonic Therapeutic, Inc.
18.69+0.30
XLO
Xilio Therapeutics, Inc.
0.65+0.00